Early DMARD therapy for rheumatoid arthritis lowers CVD risk: BMJ

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-09-04 12:30 GMT | Update On 2022-10-04 12:21 GMT

UK: Cardiovascular abnormalities are present in early rheumatoid arthritis (ERA) which can be improved using disease-modifying antirheumatic drug (DMARD) therapy, suggests a recent study in the BMJ journal Annals of the Rheumatic Diseases.

Rheumatoid arthritis (RA) patients are at a threefold increased risk of mortality as compared to the general population. This is due to the increased frequency of premature cardiovascular disease (CVD) -- particularly heart failure and atherosclerosis. The risk is as high as that of patients having major CVD risk factors including type 2 diabetes and obesity.

Epidemiological studies have shown an association between contemporary management of RA and reduction in cardiovascular (CV) events. Clinical imaging studies have demonstrated abnormal CV measures mainly in established RA with a varying association to poor prognosis factors of RA. Sven Plein, University of Leeds, Leeds, UK, and colleagues determined whether patients with ERA have CVD that is modifiable with DMARD therapy, comparing first-line etanercept (ETN) + methotrexate (MTX) with MTX strategy.

In this study, the patients from a phase IV ERA trial were randomized to ETN+MTX or MTX strategy±month 6 escalations to ETN+MTX with no CVD and maximum one traditional factor underwent cardiovascular magnetic resonance (CMR) at baseline, years 1 and 2. 30 matched controls underwent CMR. The primary outcome measure was aortic distensibility (AD) between controls and ERA, and baseline to year 1 AD change in ERA.

A total of 81 patients were recruited in the study.

Key findings of the study include:

In ERA versus controls, respectively, baseline AD was significantly lower (3.0×10⁻³ mm Hg⁻¹ vs 4.4×10⁻³ mm Hg⁻¹); LV mass significantly lower (78.2 g, n=81 vs 92.9 g, n=30); and ECV increased (27.1%, n=78 vs 24.9%, n=30).
Across all patients, AD improved significantly from baseline to year 1 (3.0×10⁻³ mm Hg⁻¹ to 3.6×10^–3 mm Hg⁻¹, respectively), maintained at year 2.
The improvement in AD did not differ between the two treatment arms and disease activity state (Disease Activity Score with 28 joint count)-erythrocyte sedimentation rate-defined responders versus non-responders.

"We report the first evidence of vascular and myocardial abnormalities in an ERA randomized controlled trial cohort and show improvement with DMARD therapy. The type of DMARD (first-line tumour necrosis factor-inhibitors or MTX) and clinical response to therapy did not affect CVD markers," concluded the authors.

The study, "Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis," is published in the Annals of the Rheumatic Diseases.

DOI: http://dx.doi.org/10.1136/annrheumdis-2020-217653

Article Source : Annals of the Rheumatic Diseases

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Early DMARD therapy for rheumatoid arthritis lowers CVD risk: BMJ

Similar News

FDA Approves First Vagus Nerve Stimulator for Rheumatoid Arthritis

FDA Grants Fast Track Status to SAP-001 for Treatment-Resistant Gout

Low Mini-Midvastus Approach for Minimally Invasive Total Knee Arthroplasty: surgical technique

JnJ seeks USFDA approval for Tremfya label update

Incidence of wound complications is very low in TJA when using the Silk Fibroin adhesive for wound closure: study

Low BMI and calcium observed in women with lactation-associated osteoporosis: Frontiers

Hydroxychloroquine Use Linked to Slower Kidney Function Decline in Lupus Nephritis Patients: Study Finds

Machine Learning Flags Key Risks for Early Macular Degeneration: Hypertension, Joint Disorders, and Dyslipidemia: Study